Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds

Rhea-AI Summary

Aptevo Therapeutics (NASDAQ:APVO) closed a warrant exercise transaction generating approximately $3.0 million in gross proceeds before placement agent fees and expenses.

Holders agreed to exercise existing warrants for up to 2,777,778 common shares at a reduced price of $1.08 per share. In exchange, Aptevo will issue new warrants to purchase up to 13,888,890 common shares, also at $1.08 per share. The new warrants become exercisable on or after required stockholder approval and expire five years after their initial exercise date.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointApproximately $3.0 million in gross proceeds raised through the existing warrant exercise transaction. 1.9× market cap

Negative

• Major pointExisting warrant exercises cover up to 2,777,778 shares at a reduced $1.08 per share, diluting holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.New warrants for up to 13,888,890 shares at $1.08 per share create potential additional dilution.
• Minor pointNew warrants require stockholder approval before becoming exercisable.
• Minor pointPlacement agent fees and expenses reduce proceeds available to Aptevo.

News Explained

Ownership dilution is conditional on approval and exercise; resale registration is a separate filing commitment.

The existing-warrant exercise is closed, while Aptevo says it will issue new warrants that, if exercised after required stockholder approval, could add up to 13,888,890 shares and reduce existing holders’ percentage ownership.

The new warrants were offered in a private placement, a sale to selected investors outside a public offering; the warrants and shares issuable upon exercise are unregistered, and Aptevo has agreed to file an SEC registration statement covering resale of those shares.

Argus 15 min delay 22 alerts

+2.98% vs previous close $0.6798 last price 8.6x rel. volume Open Argus

Details

Market Reaction – APVO

$0.65 – $0.88 Day Range

$1.44M Mkt Cap at Last Price

On Nov 12, the day this news came out, the latest delayed price for APVO is 2.98% above the previous close. Our momentum scanner has recorded 22 alerts for this stock so far that day. The latest delayed price is $0.68. Relative volume is exceptionally heavy at 8.6x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Existing warrants exercised: up to 2,777,778 shares Exercise price: $1.08 per share Inducement Warrants: up to 13,888,890 shares +3 more

Existing warrants exercised

up to 2,777,778 shares

Cash exercise at a reduced price

Exercise price

$1.08 per share

Existing Warrants

Inducement Warrants

up to 13,888,890 shares

New warrants issued in consideration for the cash exercises

Exercise price

$1.08 per share

Inducement Warrants

Gross proceeds

approximately $3.0 million

Before placement agent fees and expenses

Warrant term

five years

After the Inducement Warrants’ initial exercise date

Key Terms

warrant, exercise price, private placement, registration statement

4 terms

warrant financial

"holders of its existing common warrants"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

exercise price financial

"at a reduced exercise price of $1.08 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

private placement financial

"offered in a private placement pursuant to an applicable exemption"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

registration statement regulatory

"agreed to file a registration statement with the SEC"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, WA / ACCESS Newswire / November 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock of the Company ("common stock") at a reduced exercise price of $1.08 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 13,888,890 shares of common stock at an exercise price of $1.08 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-298483).

The aggregate gross proceeds from the transaction described herein were approximately $3.0 million, before deducting placement agent fees and expenses.

Roth Capital Partners acted as the Company's financial advisor in connection with this transaction.

The Inducement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933 (the "Securities Act"). The Inducement Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the Inducement Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

About Aptevo

Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.

In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.

This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.

The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit www.aptevotherapeutics.com.

Cautionary Note Regarding Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, the use of net proceeds from the transaction, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; the inability to obtain, maintain or enforce intellectual property protection; further assessment of preliminary or interim data or different results from later studies; adverse events and unanticipated problems; adverse developments in clinical or preclinical development, including unexpected safety issues; constraints in radioisotope availability, manufacturing or supply; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, its subsequent report on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.

Contact Information

Miriam Weber Miller
VP, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628

SOURCE: Aptevo Therapeutics

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Aptevo raise from its warrant exercise transaction?

Aptevo raised approximately $3.0 million in gross proceeds, before placement agent fees and expenses. Existing warrant holders agreed to cash exercises covering up to 2,777,778 common shares at a reduced exercise price of $1.08 per share.

What are the terms of Aptevo's new inducement warrants?

Aptevo will issue warrants to purchase up to 13,888,890 common shares at $1.08 per share. They become exercisable on or after required stockholder approval and expire five years after their initial exercise date.